Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 4
2019 1
2020 1
2021 1
2022 3
2023 1
2024 2
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Pathology of Colorectal Cancer.
Harada S, Morlote D. Harada S, et al. Adv Anat Pathol. 2020 Jan;27(1):20-26. doi: 10.1097/PAP.0000000000000247. Adv Anat Pathol. 2020. PMID: 31503031 Review.
Evaluation of MSI status, extended RAS mutation analysis, and BRAF mutation analysis are recommended by the guideline published by joint effort from professional societies. ...Extended RAS testing is an important predictive marker for antiepider …
Evaluation of MSI status, extended RAS mutation analysis, and BRAF mutation analysis are recommended by t …
Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
Mourah S, Denis MG, Narducci FE, Solassol J, Merlin JL, Sabourin JC, Scoazec JY, Ouafik L, Emile JF, Heller R, Souvignet C, Bergougnoux L, Merlio JP. Mourah S, et al. PLoS One. 2015 Mar 19;10(3):e0120232. doi: 10.1371/journal.pone.0120232. eCollection 2015. PLoS One. 2015. PMID: 25789737 Free PMC article.
Vemurafenib is approved for the treatment of metastatic melanoma in patients with BRAF V600 mutation. In pivotal clinical trials, BRAF testing has always been done with the approved cobas 4800 BRAF test. ...This prospective study shows a high co …
Vemurafenib is approved for the treatment of metastatic melanoma in patients with BRAF V600 mutation. In pivotal clinic …
Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective.
Özçevik H, Öner Tamam M, Babacan GB, Şengiz Erhan S, Acar Tayyar MN, Ertürk B. Özçevik H, et al. Turk J Med Sci. 2024 Dec 25;55(1):72-81. doi: 10.55730/1300-0144.5944. eCollection 2025. Turk J Med Sci. 2024. PMID: 40104288 Free PMC article.
The histopathological subtypes of DTC were reevaluated, and mutation analyses of the BRAF, KRAS, NRAS, and HRAS genes were performed using real-time polymerase chain reaction (PCR). ...RESULTS: Of the 77 patients, most had classical papillary thyroid carcinoma, whil …
The histopathological subtypes of DTC were reevaluated, and mutation analyses of the BRAF, KRAS, NRAS, and HRAS genes were per …
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. Scolyer RA, et al. Pathology. 2022 Feb;54(1):6-19. doi: 10.1016/j.pathol.2021.11.002. Epub 2021 Dec 20. Pathology. 2022. PMID: 34937664 Review.
Notably, it recommends that pathologists reflexively order BRAF mutation testing whenever a patient is found to have American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) stage III or IV melanoma (i.e., any metastatic spread beyond …
Notably, it recommends that pathologists reflexively order BRAF mutation testing whenever a patient is found to have American …
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB. Boussemart L, et al. Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25. Oncologist. 2019. PMID: 30683711 Free PMC article.
BACKGROUND: BRAF and MEK inhibitors are approved for BRAF V600-mutated advanced melanoma, with response rates of up to 70%. ...IMPLICATIONS FOR PRACTICE: Published guidelines for melanoma treatment recommend BRAF mutational anal …
BACKGROUND: BRAF and MEK inhibitors are approved for BRAF V600-mutated advanced melanoma, with response rates of …
Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E, de Kock R, Genet S, Borne BVD, Soud MY, Belderbos H, Stege G, de Saegher M, 't Westeinde SV, Broeren M, Eduati F, Deiman B, Scharnhorst V. Visser E, et al. Transl Oncol. 2023 Jan;27:101589. doi: 10.1016/j.tranon.2022.101589. Epub 2022 Nov 19. Transl Oncol. 2023. PMID: 36413862 Free PMC article.
CtDNA from 458 primary lung cancer patients was analyzed using a panel of multiplex ddPCRs for EGFR (Ex19Del, G719S, L858R, L861Q and S768I), KRAS G12/G13 and BRAF V600 mutations. For 142 of 175 advanced stage non-squamous NSCLC patients tDNA-NGS results were …
CtDNA from 458 primary lung cancer patients was analyzed using a panel of multiplex ddPCRs for EGFR (Ex19Del, G719S, L858R, L861Q and S768I) …
[Systemic treatment of inoperable metastasized malignant melanoma].
Gutzmer R, Rauschenberg R, Meier F. Gutzmer R, et al. Hautarzt. 2016 Jul;67(7):529-35. doi: 10.1007/s00105-016-3795-1. Hautarzt. 2016. PMID: 27164828 Review. German.
MATERIALS AND METHODS: Clinical studies and guidelines in the therapy of malignant melanoma are reviewed. RESULTS: Medical therapy of inoperable melanoma changed due to developments in immunotherapies (checkpoint inhibitors) and molecular-targeted therapies (BRAF an …
MATERIALS AND METHODS: Clinical studies and guidelines in the therapy of malignant melanoma are reviewed. RESULTS: Medical therapy of …
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Anker CJ, et al. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Int J Radiat Oncol Biol Phys. 2016. PMID: 27131079 Free PMC article. Review.
BRAF kinase gene V600 point mutations drive approximately 40% to 50% of all melanomas, and BRAF inhibitors (BRAFi) have been found to significantly improve survival outcomes. ...This literature review provides a detailed analysis of potential in …
BRAF kinase gene V600 point mutations drive approximately 40% to 50% of all melanomas, and BRAF inhibitors (BRAF …
A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma-Application to a Pharmacokinetic Study.
Hefnawy MM, Alanazi MM, Al-Hossaini AM, Alnasser AI, El-Azab AS, Jardan YAB, Attwa MW, El-Gendy MA. Hefnawy MM, et al. Molecules. 2022 Dec 22;28(1):79. doi: 10.3390/molecules28010079. Molecules. 2022. PMID: 36615272 Free PMC article.
The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi( ), ENF) plus binimetinib (Mektovi( ), BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activ …
The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi( ), ENF) plus binimetinib (Mektovi( ), …
Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM, Haverkate H, Rosing H, Schellens JH, Beijnen JH. Nijenhuis CM, et al. J Pharm Biomed Anal. 2016 Jun 5;125:270-9. doi: 10.1016/j.jpba.2016.03.049. Epub 2016 Mar 25. J Pharm Biomed Anal. 2016. PMID: 27058232
Dabrafenib (Tafinlar( )) and trametinib (Mekinist( )) are registered for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma. To support therapeutic drug monitoring (TDM) and clinical pharmacological trials, an assay …
Dabrafenib (Tafinlar( )) and trametinib (Mekinist( )) are registered for the treatment of patients with BRAF V600 mutation …
14 results